Clinical Trial Update: Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effects of dapagliflozin on symptoms and biomarkers in patients with chronic heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Saint Luke's Health System | Conditions: Chronic Heart Failure With Reduced Systolic Function | Phase 4 | Status: COMPLETED | Results posted: 2021-12-01